rat ctx i elisa kit  (Elabscience Biotechnology)

Journal: Molecular Medicine

Article Title: CD5L insufficiency exacerbates skeletal joint damage in rheumatoid arthritis

doi: 10.1186/s10020-026-01456-x

Figure Lengend Snippet: Immune profile of WT and CD5L⁻ mice during CIA. A Serum CD5L levels measured in WT mice after immunization. p -values were obtained using the Kruskal–Wallis test with Dunn’s multiple comparisons. B Frequencies of blood leukocyte subsets in WT ( n = 10) and CD5L⁻ ( n = 10) mice. Leukocytes were phenotyped by flow cytometry: CD11b + cells, monocytes (Siglec-F⁻Ly6G⁻F4/80⁺CD11b⁺); inflammatory monocytes (Siglec-F⁻Ly6G⁻F4/80⁺CD11b⁺Ly6C⁺); and Ly6C⁻ monocytes (Siglec-F⁻Ly6G⁻F4/80⁺CD11b⁺Ly6C⁻). Shaded area indicates mean and SEM of total leukocyte frequency. p -values were calculated using Šídák’s multiple-comparisons test. C Serum cytokine levels in WT ( n = 6) and CD5L⁻ ( n = 6) mice. p -values were calculated using the Mann–Whitney test. D Serum RANKL and cross-linked C-telopeptide of type I collagen (CTX-I) levels on day 56 after immunization. p -values were obtained using an unpaired t -test with Welch’s correction. E Splenic gene expression in non-immunized WT ( n = 5) and CD5L⁻ ( n = 5) mice, measured by RT-qPCR and normalized to Actb (β-actin). p -values were calculated using a two-tailed unpaired t -test with Welch’s correction

Article Snippet: C-telopeptide cross-link type I collagen (CTX-I) was measured by an ELISA (IDS Serum CrossLaps, Immunodiagnostic Systems, Boldon, UK) in undiluted samples; detection limit, 0.11 ng/ml.

Techniques: Flow Cytometry, MANN-WHITNEY, Gene Expression, Quantitative RT-PCR, Two Tailed Test

Journal: The lancet. Diabetes & endocrinology

Article Title: 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial

doi: 10.1016/S2213-8587(25)00319-5

Figure Lengend Snippet: Mean absolute change from baseline in β-isomer of CTX (A) and P1NP (B) in the two treatment groups. Error bars indicate the 95% CIs (some error bars are contained within the symbol). Asterisks indicate a statistically significant between-group difference at that timepoint. 3-month ROMO=3 months of romosozumab followed by 9 months of denosumab. 12-month ROMO=12 months of romosozumab. CTX=C-terminal telopeptide of type I collagen. P1NP=procollagen type I N-terminal propeptide.

Article Snippet: Serum markers of bone turnover—β-isomer of C-terminal telopeptide of type I collagen (CTX) and procollagen type I N-terminal propeptide (P1NP)—were measured in morning fasting samples and assayed in batches at study completion by electrochemiluminescence (iSYS, Immunodiagnostic Systems, Scottsdale, AZ, USA).

Techniques: